Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

Preventing AKI after TAVR may help lessen the impact of chronic kidney disease

If researchers can find ways to prevent AKI after TAVR, it could help decrease the risk of poor outcomes in more ways than one. 

womanconsultation.jpg

Underdiagnosed and undertreated: How cardiologists and primary care physicians are working together to identify patients with severe aortic stenosis

Sponsored by Medtronic

Aortic stenosis (AS) is one of the most common—and growing—cardiac conditions. In particular, the prevalence of severe AS rises markedly among elderly Americans, affecting an estimated 3.4% of Americans 75 and older.[1]

Q&A: What the impressive durability of self-expanding TAVR valves means for patient care, shared decision-making

Sponsored by Medtronic

Updates about transcatheter aortic valve replacement (TAVR) are always big news, but the new five-year data from the CoreValve™ US Pivotal and SURTAVI trials came as a welcome surprise to many cardiologists. 

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

Earlier interventions may boost survival when TAVR patients experience a stroke

New research in JACC: Cardiovascular Interventions suggests improved collaborations between cardiologists and neurologists could help TAVR patients live longer after a periprocedural stroke. 

CT imaging showing the congenital heart defect of left heart hypoplastic syndrome.

VIDEO: Congenital heart imaging with cardiac CT

As the population of patients with adult congenital heart disease grows, they are presenting to adult cardiology clinics and being imaged with CT. Many also do not have access or cannot be imaged by MRI, said Renee Bullock-Palmer, MD.

The Medtronic Intrepid transcatheter mitral valve replacement (TMVR) system performed well in two studies presendted at TCT 2022. #TCT #TCT22 #TCT2022 #TMVR

Intrepid transcatheter mitral valve pilot study shows positive 3-year outcomes

New data on the Medtronic Intrepid transcatheter mitral valve replacement system from the Intrepid Pilot Study and Intermediate-Term Outcomes of the Intrepid Early Feasibility Study, were presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference.

Impella Heart Pump Abiomed RECOVER IV RCT cardiogenic shock

Regulatory Roundup: FDA clears AI model for RV/LV ratios, approves calcium-blocking TAVR valve and much more

Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic. 

The tricuspid valve anatomy is ofrten complicated for transcatheter structural heart interventions (TTVR) by the placement of pacemaker or ICD leads.

VIDEO: Addressing tricuspid valve regurgitation with new transcatheter interventions 

Joao Cavalcante, MD, of the Minneapolis Heart Institute, discusses new structural heart interventions to treat tricuspid valve regurgitation.

Around the web

Radiology practices are already operating on razor thin margins, with price increases prompting calls for congressional action to prevent further damage. 

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?